52 results about "Essential tremor" patented technology

A peripheral nerve stimulator can be used to stimulate a peripheral nerve to treat essential tremor, Parkinson tremor, and other forms of tremor. The peripheral nerve stimulator can be either a noninvasive surface stimulator or an implanted stimulator. Stimulation can be electrical, mechanical, or chemical. Stimulation can be delivered using either an open loop system or a closed loop system with feedback.

A method for treating essential tremor or restless leg syndrome using spinal cord stimulation includes implanting a lead near a spinal cord of a patient. The lead includes a plurality of electrodes disposed on a distal end of the lead and electrically coupled to at least one contact terminal disposed on a proximal end of the lead. Electrical signals are provided from a control module coupled to the lead to stimulate a portion of the spinal cord of the patient using at least one of the electrodes. The electrical signals reduce, alleviate, or eliminate at least one adverse effect of essential tremor or restless leg syndrome.

The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

A method for treating essential tremor comprising the step of applying deep brain stimulation to the ascending dentate/interpositus-ventral intermedius fibres of the brain at a location remote from the ventral intermedius nucleus of the thalamus. A method for identifying an area of a patient's brain to be targeted with deep brain stimulation for the treatment of essential tremor comprising the step of using a scan of a patient's brain to identify a target area in relation to the subthalmic nucleus and the red nucleus. A method of treating essential tremor by using deep brain stimulation. A method of treating essential tumor by using a DBS electrode targeted to the dentate/interpositus-ventral intermedius fibres. A kit used in treating essential tremor.

A peripheral nerve stimulator can be used to stimulate a peripheral nerve to treat essential tremor, Parkinsonian tremor, and other forms of tremor. The stimulator can have electrodes that are placed circumferentially around the patient's wrist or arm. Specific nerves in the wrist or arm can be targeted by appropriate spacing of the electrodes. Positioning the electrodes on generally opposing sides of the target nerve can result in improved stimulation of the nerve. The stimulation pattern may alternate between the nerves. Improved stimulation algorithms can incorporate tremor feedback, external data, predictive adaptation, and long-term monitoring data.

The invention belongs to the technical field of medicine, specifically discloses an optically sensitive pure S-(-)-arotinolol acid salt, and researches a preparation method and applications of the arotinolol acid salt at the same time. Through a large amount of research and experimental results, the technicians found that the prepared S-(-)-arotinolol acid salt is a crystal product, and can be used for preparation of drugs or heath care product for treating essential hypertension, angina pectoris, tachycardia induced arrhythmia, and essential tremor.

Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).

A high-precision low-power-consumption multi-channel brain deep electroneurographic signal wireless collecting system comprises eight-channel brain deep cerebral nuclei electric signal collecting electrodes, any collecting electrode is selected freely by an analog multiway switch to collect brain deep cerebral nuclei electric signals, collected analog signals are directly input into an AD collecting module for preprocessing and A/D conversion, and converted data are stored in a data storage module through an MCU. After data are collected for certain time, the stored data are transmitted to the other MCU through a sending RF wireless transmission module and a receiving RF wireless transmission module, and then the data are transmitted into an upper computer to be displayed and further processed through an USB interface. The brain deep cerebral nuclei electric signals are collected, and an effective cerebral nuclei signal collecting tool is provided for exploring the therapeutic mechanism and action principle of a DBS, and the pathogenesis of the Parkinson's disease, an essential tremor and a series of neurological diseases.

The present invention relates to the use of fruit extract from Vitex agnus castus and/or one or more isolated and/or synthetically prepared bicylic diterpenes from Vitex agnus castus for the preparation of a medicament for the treatment of movement disorders. In particular, the invention is directed to the preparation of medicaments for treating Parkinson disease (PD), Periodic Limb Movement disorder (PLMD) and Restless Leg Syndrome (RLS), Huntington disease (HD) and Essential Tremor (ET), preferably familiar ET. Furthermore, the invention concerns a pharmaceutical composition comprising a fruit extract from Vitex agnus castus and/or one or more isolated and/or synthetically prepared bicylic diterpenes from Vitex agnus castus and at least one pharmaceutically compatible dopamine D2 and/or D3 receptor agonist.

Essential tremor can effectively be treated with high doses of Riboflavin (vitamin B2), either on its own or coupled with one or more other B vitamins and/or coenzyme Q10 (CoQ10). The treatment constitutes a significant improvement over prior treatment methods in that it not only alleviates essential tremor, but results in better performance of the affected body portion and may delay the progression of the disease. The preferred addition of other B vitamins and/or CoQ10 also provides balance to the nutrient energy requirements of a patient's body.

The invention relates to a tablet medicine compound containing levetiracetam. Specifically, the medicine compound comprises levetiracetam, disintegrant, binder, glidant and lubricant. More specifically, the medicine compound comprises 500 parts by weight of levetiracetam, 10-50 parts by weight of disintegrant, 2 -10 parts by weight of binder, 1-5 parts by weight of glidant, and 1 -5 parts by weight of lubricant. The medicine compound has good pharmaceutical characteristics, and can be used for treating or preventing epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, essential tremor, bipolar disorder, chronic pain, neuropathic pain, bronchia, asthma or allergic diseases.

This disclosure relates to Compound (I), pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor; depression; and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.

The present invention relates to applications of compound gymnadenia conopsea (l.) r. br pills in preparation of essential tremor treating drugs, and belongs to the field of medicine. According to the present invention, the technical prejudice in the application field in the prior art is overcome; and clinical research results show that symptoms of the essential tremor can be significantly improved and the essential tremor treating effect can be achieved by separately using the compound gymnadenia conopsea (l.) r. br pills or combining the compound gymnadenia conopsea (l.) r. br pills and other drugs, the effect of the single use of the compound gymnadenia conopsea (l.) r. br pills is equivalent to the effect of the conventional drug propranolol hydrochloride, and the effect of the combination of the compound gymnadenia conopsea (l.) r. br pills, the nerve calming pills and/or propranolol hydrochloride is superior to the effect of the conventional drug propranolol hydrochloride (P <0.05).

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula I:

The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.